Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, April 8th, 2025, at 10:15 am ET.

The conference, scheduled to run from April 7-10, 2025, will also feature one-on-one meetings with company management. A live webcast and archived recording of the event will be accessible through the Events & Presentations section of Phathom's website, with the recording remaining available for 90 days after the meeting.

Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of novel treatments for gastrointestinal (GI) diseases.

Phathom Pharmaceuticals (Nasdaq: PHAT) has announced the approval of inducement awards connected to Steven Basta's appointment as President and CEO. The compensation package includes:

• A non-qualified stock option to purchase 1,085,000 shares, with 25% vesting on April 1, 2026, and the remainder vesting in 36 monthly installments
• 360,000 performance stock units tied to stock price hurdles
• 180,000 performance stock units (with potential 200% target earnings) linked to revenue targets through December 31, 2027

The company, focused on gastrointestinal disease treatments, markets VOQUEZNA® tablets for heartburn and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment.

Phathom Pharmaceuticals (NASDAQ: PHAT) has announced a significant leadership change with the appointment of Steven Basta as President, CEO, and Board member, effective immediately. Basta replaces Terrie Curran, who is stepping down from her positions for personal reasons after five years of leadership.

The company, which focuses on developing and commercializing novel treatments for gastrointestinal (GI) diseases, views this transition as an opportunity to accelerate commercial growth. Chairman Michael Cola expressed confidence in Basta's extensive commercial expertise and track record in developing novel treatments.

Under this transition, Phathom aims to expand opportunities for their product VOQUEZNA® and enhance shareholder value. The new CEO emphasized his commitment to unlocking VOQUEZNA's full potential in addressing unmet needs in GI disease treatment.

Phathom Pharmaceuticals (NASDAQ: PHAT) has announced a partnership with actor and comedian Kenan Thompson to launch the 'GERD IS NO JOKE' campaign, raising awareness about gastroesophageal reflux disease (GERD) and their treatment VOQUEZNA® (vonoprazan).

Thompson, the longest-running SNL cast member, reveals his personal struggle with Non-Erosive GERD and his successful treatment with VOQUEZNA, the first FDA-approved potassium competitive acid blocker (PCAB) for both types of GERD. The campaign aims to reach over 65 million Americans living with GERD through multiple channels, including broadcast television, streaming platforms, and social media.

VOQUEZNA is approved for adults for:

• Relief of heartburn associated with Non-Erosive GERD
• Treatment of all severities of Erosive Esophagitis
• Relief of related heartburn

Phathom Pharmaceuticals (PHAT) reported strong Q4 and full year 2024 results for VOQUEZNA®, its gastrointestinal treatment. The company achieved $55.3 million in net revenues for 2024, including $29.7 million in Q4 (81% increase from Q3).

Key highlights include:

• Over 300,000 filled prescriptions launch-to-date (110% increase since last report)
• More than 20,000 healthcare providers have prescribed VOQUEZNA
• Commercial coverage reaching 120+ million lives (80% of U.S. commercial lives)
• Q4 2024 net loss of $74.5 million compared to $79.6 million in Q4 2023

The company plans to initiate a Phase 2 EoE trial in Q2 2025 and has launched a direct-to-consumer campaign. Cash position stands at $297.3 million as of December 31, 2024, with an additional $100 million available under term loan.

Phathom Pharmaceuticals (NASDAQ: PHAT) has announced it will host a live webcast on Thursday, March 6, 2025, at 8:30 am ET to present its fourth quarter and full year 2024 financial results along with a business update.

The company specializes in developing and commercializing treatments for gastrointestinal diseases. Their key product is vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA®. The treatment is approved for heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and comes in TRIPLE PAK® and DUAL PAK® combinations for H. pylori infection treatment.

Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management team will engage in a fireside chat on Thursday, February 6, 2025, at 10:00 am ET and conduct one-on-one meetings throughout the conference, which runs from February 5-6, 2025, in New York, NY.

The biopharmaceutical company, which specializes in developing and commercializing novel treatments for gastrointestinal (GI) diseases, will provide a live webcast of the event. Interested parties can access both the live presentation and an archived recording through the Events & Presentations section of Phathom's website. The recording will remain available for 90 days after the event's conclusion.

Phathom Pharmaceuticals (NASDAQ: PHAT) has submitted a Citizen Petition to the FDA requesting correction of Orange Book listings for VOQUEZNA tablets. The company seeks to ensure its vonoprazan tablets receive the full 10-year New Chemical Entity (NCE) exclusivity period until May 3, 2032, aligning with the exclusivity granted to VOQUEZNA TRIPLE PAK and DUAL PAK in May 2022.

The exclusivity period includes a five-year standard period for NCEs plus an additional five years under the Generating Antibiotic Incentives Now (GAIN) Act. This would prevent submission of any Abbreviated New Drug Application or 505(b)(2) New Drug Application referencing vonoprazan during this period. The FDA must respond to the petition within 180 days.

Phathom Pharmaceuticals reported strong Q3 2024 results with net revenues of $16.4 million, showing over 120% sequential quarterly increase from Q7.3 million in Q2. The company's VOQUEZNA® products reached over 143,000 prescriptions filled to date, a 138% increase since last quarter. Commercial coverage expanded to over 80% of U.S. commercial lives, covering approximately 120 million people. The prescriber base grew to more than 13,600, up 65% from previous quarter. However, net loss increased to $85.6 million compared to $43.2 million in Q3 2023, with SG&A expenses rising significantly to $76.1 million due to commercial infrastructure buildout.